

WEST NORTHAMPTONSHIRE HEALTH AND WELLBEING BOARD

24th June 2021

Report Title	West Northamptonshire Pharmaceutical Needs Assessment
Report Author	Charlotte Goodson, adviser, PCC CIC, charlotte.goodson@pcc.nhs.uk Deborah Mbofana, public health practitioner – health improvement, Deborah.Mbofana@northnorthants.gov.uk Anne Hartley , intelligence and insight manager, Anne.Hartley@northnorthants.gov.uk

Contributors/Checkers/Approvers		
Director/SME	Lucy Wightman	7 th June 2021

List of Appendices

Appendix A – West Northamptonshire Health and Wellbeing Board pharmaceutical needs assessment (May 2021 version)

1. Purpose of Report

- 1.1. The health and wellbeing board is asked to review and sign-off its first pharmaceutical needs assessment.

2. Executive Summary

- 1.2. The health and wellbeing board is required to publish its first pharmaceutical needs assessment for West Northamptonshire by 1 April 2022.
- 1.3. A project advisory group was established and work started on producing the document in the summer of 2020.
- 1.4. A wide range of stakeholders have been involved in its production.
- 1.5. As well as surveying the views of the public, pharmacies and dispensing GP practices, a formal 60 day consultation was undertaken in February and March 2021.
- 1.6. The pharmaceutical needs assessment was reviewed in light of the responses to the consultation and is now presented for review and sign-off.

3. Recommendations

- 3.1 It is recommended that the board signs off, and approves publication of, the first West Northamptonshire Health and Wellbeing Board pharmaceutical needs assessment.
- 3.2 It is a statutory duty of Health and Wellbeing Boards to oversee production and publication of a Pharmaceutical Needs Assessment for their local area.

4. Report Background

- 4.1 Under the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013, as amended, the Health and Wellbeing board has a statutory duty to prepare and publish its first pharmaceutical needs assessment by 1 April 2022.
- 4.2 Northamptonshire County Council established a project advisory group to oversee the development of the pharmaceutical needs assessments for the two new unitary authorities and work started on them in the summer of 2020. The services of Primary Care Commissioning CIC were engaged to ensure delivery of the document by the regulatory timescale, which at that time was 1 April 2021 although this was subsequently delayed by a year. The Northamptonshire Health and Wellbeing Board was updated on progress in September 2020 and at that meeting it was agreed that the project advisory group would sign off the consultation versions of both documents.
- 4.3 The formal sixty day consultation was undertaken in February and March 2021 and the responses to that consultation have been taken into account in the final version of the document which is now presented to the board for consideration and sign-off.

5. Issues and Choices

- 5.1 The board is asked to note the conclusions of the pharmaceutical needs assessment and sign the document off for publication.

6. Implications (including financial implications)

6.1 Resources and Financial

- 6.1.1 There are no resource or financial implications for the Health and Wellbeing Board in relation to the pharmaceutical needs assessment. Any applications for new premises, relocation of existing premises or changes of ownership or existing premises submitted by pharmacies or dispensing appliance contractors will be determined NHS England and NHS Improvement and the commissioning of pharmaceutical services falls within the remit of that organisation.

6.2 Legal

- 6.2.1 Other than the statutory duty on the Health and Wellbeing board to publish its first pharmaceutical needs assessment by 1 April 2022, there are no legal implications for the Health and Wellbeing board in relation to the pharmaceutical needs assessment.

6.3 Risk

- 6.3.1 There are two potential risks to the board. The first is the failure to publish its first pharmaceutical needs assessment by 1 April 2022. That risk has been eliminated by the work starting and being undertaken in a timely manner.
- 6.3.2 The second risk is a challenge on the pharmaceutical needs assessment itself, or the process by which it was undertaken. The steps that have been undertaken to minimise this risk include:
 - 6.3.2.1 The establishment of the project advisory group which included representation from public health, NHS England and NHS Improvement, Northamptonshire and Milton Keynes Local Pharmaceutical Committee, Northants Local Medical Committee, Healthwatch Northamptonshire and NHS Northamptonshire Clinical Commissioning Group.
 - 6.3.2.2 A survey to capture the views of members of the public.
 - 6.3.2.3 A survey to capture the views of pharmacies and dispensing GP practices.
 - 6.3.2.4 The formal 60 day consultation on a draft of the pharmaceutical needs assessment. A range of statutory and other organisations were notified of the consultation and invited to submit their views and it was also promoted to members of the public.
- 6.3.3 The project advisory group is therefore satisfied that it has minimised this second risk as much as it can.

6.4 **Consultation**

- 6.4.1 The following were consulted on a draft of the pharmaceutical needs assessment:
 - 6.4.1.1 Northamptonshire and Milton Keynes Local Pharmaceutical Committee,
 - 6.4.1.2 Northants Local Medical Committee,
 - 6.4.1.3 the pharmacies, dispensing appliance contractors and dispensing GP practices in West Northamptonshire,
 - 6.4.1.4 Healthwatch Northamptonshire,
 - 6.4.1.5 Northampton General Hospital NHS Trust,
 - 6.4.1.6 Northamptonshire Healthcare NHS Foundation Trust,
 - 6.4.1.7 NHS England and NHS Improvement – Midlands,
 - 6.4.1.8 NHS England and NHS Improvement – East,
 - 6.4.1.9 NHS England and NHS Improvement – South East,
 - 6.4.1.10 NHS Northamptonshire Clinical Commissioning Group,
 - 6.4.1.11 Warwickshire Health and Wellbeing Board,
 - 6.4.1.12 Leicestershire Health and Wellbeing Board,
 - 6.4.1.13 Bedford Borough Health and Wellbeing Board,
 - 6.4.1.14 Buckinghamshire Health and Wellbeing Board,
 - 6.4.1.15 Oxfordshire Health and Wellbeing Board, and
 - 6.4.1.16 Those members of the public who are registered to be notified of consultations.
- 6.4.2 A report on the consultation is included as an appendix to the pharmaceutical needs assessment.

6.5 **Consideration by Overview and Scrutiny**

- 6.5.1 The pharmaceutical needs assessment has not been presented to the Overview and Scrutiny Committee.

6.6 **Climate Impact**

6.6.1 There is no climate/environmental impact in relation to the pharmaceutical needs assessment.

6.7 **Community Impact**

6.7.1 The pharmaceutical needs assessment has divided West Northamptonshire into localities and has identified the needs of those populations, how they may change over the three year lifetime of the document, and looked at the current provision of pharmaceutical services both within and outside the area.

6.7.2 It has also identified the specific needs of those who share a protected characteristic for pharmaceutical services.

7. **Background Papers**

7.1 All data sources within the pharmaceutical needs assessment are fully referenced.